Many studies have shown that the use of SGLT2 inhibitors can reduce the risk of severe cardiac and renal prognosis, such as reducing the risk of vascular death and hospitalization for heart failure (HHF) (9–11). This evidence concerns the gene SLC5A2 and heart failure.